首页> 外文OA文献 >The embryonic Brachyury transcription factor is a novel biomarker of GIST aggressiveness and poor survival
【2h】

The embryonic Brachyury transcription factor is a novel biomarker of GIST aggressiveness and poor survival

机译:胚性Brachyury转录因子是GIST侵略性和存活率低的新型生物标志物

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The T-box transcription factor Brachyury was recently reported to be upregulated and associated with prognosis in solid tumors. Here, we proposed to evaluate the potential use of Brachyury protein expression as a new prognostic biomarker in gastrointestinal stromal tumors (GIST). Brachyury protein expression was analyzed by immunohistochemistry in a cohort of 63 bona fide GIST patients. Brachyury expression profiles were correlated with patients' clinicopathological features and prognostic impact. Additionally, an in silico analysis was performed using the Oncomine database to assess Brachyury alterations at DNA and mRNA levels in GISTs. We found that Brachyury was overexpressed in the majority (81.0 %) of primary GISTs. We observed Brachyury staining in the nucleus alone in 4.8 % of cases, 23.8 % depicted only cytoplasm staining, and 52.4 % of cases exhibited both nucleus and cytoplasm immunostaining. The presence of Brachyury was associated with aggressive GIST clinicopathological features. Particularly, Brachyury nuclear (with or without cytoplasm) staining was associated with the presence of metastasis, while cytoplasm sublocalization alone was correlated with poor patient survival. Herein, we demonstrate that Brachyury is overexpressed in GISTs and is associated with worse outcome, constituting a novel prognostic biomarker and a putative target for GIST treatment.
机译:最近报道了T-box转录因子Brachyury被上调并且与实体瘤的预后相关。在这里,我们建议评估Brachyury蛋白表达作为胃肠道间质瘤(GIST)中新的预后生物标志物的潜在用途。通过免疫组化分析了63名真正的GIST患者的Brachyury蛋白表达。 Brachyury表达谱与患者的临床病理特征和预后影响相关。另外,使用Oncomine数据库进行计算机分析,以评估GIST中DNA和mRNA水平的Brachyury改变。我们发现Brachyury在大多数原发性GIST中过表达(81.0%)。我们观察到仅4.8%的病例仅在细胞核中出现Brachyury染色,23.8%的病例仅显示细胞质染色,而52.4%的病例同时显示了核和细胞质免疫染色。 Brachyury的存在与侵略性GIST临床病理特征相关。特别地,Brachyury核(有或没有细胞质)染色与转移的存在有关,而仅细胞质亚定位与不良的患者存活率相关。在本文中,我们证明了Brachyury在GIST中过表达,并且与较差的预后相关,构成了新的预后生物标志物和GIST治疗的假定靶标。

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号